Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis

To improve the anti-metastasis effects of honokiol (HNK) on breast cancer, we designed cationic liposomes (Lip) in which HNK was encapsulated into Lip, and its surface was modified with negatively charged polysialic acid (PSA-Lip-HNK) for efficient treatment of breast cancer. PSA-Lip-HNK possessed a homogeneous spherical shape and high encapsulation efficiency. In vitro 4T1 cell experiments indicated that PSA-Lip-HNK increased cellular uptake and cytotoxicity via the endocytosis pathway mediated by PSA and selectin receptors. Furthermore, the significant antitumor metastasis impact of PSA-Lip-HNK was confirmed by wound healing and cell migration and invasion. Enhanced in vivo tumor accumulation of the PSA-Lip-HNK was observed in 4T1 tumor-bearing mice by living fluorescence imaging. For in vivo antitumor experiments using 4T1 tumor-bearing mice, PSA-Lip-HNK exhibited a higher tumor growth and metastasis inhibition compared with unmodified liposomes. Therefore, we believe that PSA-Lip-HNK well combined biocompatible PSA nano-delivery and chemotherapy, providing a promising drug delivery approach for metastatic breast cancer therapy.

Automated summary

To enhance the anti-metastasis effects of honokiol (HNK) on breast cancer, researchers designed cationic liposomes encapsulating HNK and modified their surface with negatively charged polysialic acid (PSA-Lip-HNK). In vitro experiments showed that PSA-Lip-HNK increased cellular uptake and cytotoxicity through the endocytosis pathway mediated by PSA and selectin receptors. In vivo experiments on tumor-bearing mice demonstrated that PSA-Lip-HNK effectively inhibited tumor growth and metastasis. Therefore, PSA-Lip-HNK provides a promising drug delivery approach for metastatic breast cancer therapy.